Shares of Kamada Ltd. (KMDA) reached a 52-week high of $7.96 during intraday trading yesterday, reflecting investor optimism surrounding the company's continued growth and financial outlook for 2024 and 2025.
This commercial-stage global biopharmaceutical company is focused on specialty plasma-derived therapeutics.
For the full year 2024, the company continues to expect total revenues in the range of $158 million to $162 million, with Adjusted EBITDA projected to range between $38 million and $42 million The total revenue was $142.5 million, and Adjusted EBITDA was $24.1 million in the full year 2023.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.